Editorial
Copyright ©2013 Baishideng Publishing Group Co.
World J Clin Oncol. May 10, 2013; 4(2): 29-42
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.29
Table 1 Selected phase III and randomized phase II trials comparing epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy as first-line therapy in patients with advanced non-small cell lung cancer
TrialnType of studyStudy designOS (mo)P valuePFS (mo)P valueORR (%)P value
HR (95%CI)HR (95%CI)HR (95%CI)
Fukuoka et al[34]261RetrospectiveGefitinib vs PC21.6 vs 21.99.6 vs 6.371.2 vs 47.3
1.00 (0.76-1.33)0.990.48 (0.36-0.64)0.00012.75 (1.65-4.6)0.0001
Han et al[98]42RetrospectiveGefitinib vs Cis + G27.2 vs 25.68.0 vs 6.384.6 vs 37.5
1.04 (0.49-2.18)NA0.54 (0.26-1.1)0.0869.16 (2.10-39.84)0.002
Mitsudomi et al[99]172ProspectiveGefitinib vs Cis + D35.5 vs 38.89.6 vs 6.662.1 vs 32.1
1.18 (0.76-1.8)0.440.52 (0.37-0.71)0.0013.44 (1.60-7.37)0.0001
Maemondo et al[35], Inoue et al[100]228ProspectiveGefitinib vs PC27.7 vs 26.610.8 vs 5.473.7 vs 30.7
0.88 (0.63-1.24)0.480.32 (0.23-0.43)0.0016.32 (3.55-11.25)0.001
Chen et al[28]154ProspectiveErlotinib vs C + G22.7 vs 28.8513.7 vs 4.683 vs 36
1.04 (0.69-1.58)0.690.16 (0.10-0.26)0.0001NA0.0001
Rosell et al[29]173ProspectiveErlotinib vs platinum-based doublets19.3 vs 19.59.7 vs 5.2581vs 151
1.04 (0.65-1.68)0.870.37 (0.25-0.54)0.0001NANA
Yang et a2l[101]345ProspectiveAfatinib vs Cis + PNM11.13vs 6.9356.13vs 22.63
0.58 (0.43-0.78)0.0004NA0.001
Jänne et al[102]345ProspectiveErlotinib vs erlotinib + PC24.6 vs 19.85.0 vs 6.635 vs 46
NANANANANANA